Phenytoin levels in catamenial epilepsy

Area of Science:

• Epilepsy Research
• Pharmacokinetics
• Neuroendocrinology

Background:

• Catamenial epilepsy is characterized by seizure exacerbation related to the menstrual cycle.
• Fluctuations in hormone levels during the menstrual cycle can impact seizure threshold.
• Phenytoin (PHT) is a commonly used antiepileptic drug.

Purpose of the Study:

• To investigate the impact of the menstrual cycle on phenytoin (PHT) plasma levels.
• To determine if PHT level fluctuations correlate with seizure activity in catamenial epilepsy.
• To compare PHT pharmacokinetics during different phases of the menstrual cycle.

Main Methods:

• Studied PHT levels in eight patients with catamenial epilepsy and eight age-matched controls.
• Conducted pharmacokinetic studies of PHT in five catamenial epilepsy patients.
• Measured PHT levels during ovulatory and menstrual phases of the cycle.

Main Results:

• A significant mean fall in PHT levels (3.44 +/- 3.25 micrograms/ml) was observed during the menstrual phase in the catamenial epilepsy group compared to controls (0.91 +/- 2.03 micrograms/ml).
• The decrease in PHT levels during menstruation was statistically significant (p < 0.05) in the catamenial group.
• A rapid, though not statistically significant, clearance of PHT was noted during menses compared to the ovulatory period.

Conclusions:

• Plasma PHT levels decrease during the menstrual phase in women with catamenial epilepsy.
• These PHT level fluctuations, even within the therapeutic range, may precipitate or worsen seizures during menstruation.
• Further research is warranted to optimize PHT dosing strategies for catamenial epilepsy management.